Sugi Predict

Sugi Predict / Compounds / SCHEMBL177772

SCHEMBL177772

SCHEMBL177772

CCN(C=O)C(O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHCY P23526 7/20 0.61
▸ HIF1A Q16665 1/20 0.57
▸ TMEM97 Q5BJF2 1/20 0.57
▸ SIGMAR1 Q99720 1/20 0.57
▸ TSHR P16473 4/20 0.56
▸ HSP90B1 P14625 3/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HSP90AA1 P07900 2/20 0.56
▸ ADORA3 P0DMS8 2/20 0.56
▸ ADORA2A P29274 2/20 0.56
▸ ADORA2B P29275 2/20 0.56
▸ ADORA1 P30542 2/20 0.56
▸ LMNA P02545 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ DOT1L Q8TEK3 1/20 0.56
▸ TMIGD3 P0DMS9 1/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28901883 1.00 AHCY (0.61) AHCYHIF1ATMEM97SIGMAR1TSHR
SCHEMBL29877256 1.00 AHCY (0.61) AHCYHIF1ATMEM97SIGMAR1TSHR
SCHEMBL7744261 0.89 AHCY (0.46) AHCYADORA2AADORA2B
SCHEMBL1972796 0.88 AHCY (0.63) AHCYHIF1ATMEM97SIGMAR1TSHR
SCHEMBL19066616 0.88 AHCY (0.58) AHCYHIF1ATMEM97SIGMAR1TSHR
SCHEMBL258935 0.86 ADORA3 (0.59) ADORA3ADORA2AADORA2BADORA1
SCHEMBL6636036 0.86 ADORA2A (0.52) ADORA3ADORA2AADORA2BADORA1
SCHEMBL6698657 0.85 AHCY (0.55) AHCYHIF1ATMEM97SIGMAR1TSHR
SCHEMBL6402599 0.84 AHCY (0.62) AHCYHIF1ATMEM97SIGMAR1TSHR
SCHEMBL1068915 0.83 AHCY (0.60) AHCYHIF1ATMEM97SIGMAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 867 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 — — EP claimed
US-20250262274-A1 Designed Biosensors for Enhanced T Cell Therapy ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2025-08-21 — — US claimed
EP-4526335-A1 DESIGNED BIOSENSORS FOR ENHANCED T CELL THERAPY Centre Hospitalier Universitaire Vaudois (CH) 2025-03-26 — — EP claimed
US-20250090673-A1 CONJUGATE FOR TARGETING CENTRAL NERVOUS SYSTEM SUNTEC MEDICAL INC (US) 2025-03-20 — — US claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 — — WO claimed
WO-2023222829-A1 DESIGNED BIOSENSORS FOR ENHANCED T CELL THERAPY CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH) 2023-11-23 — — WO claimed
WO-2023196235-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-12 — — WO claimed
US-20230310471-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-05 — — US claimed
US-11771678-B2 Therapeutic agent for neuropathy in organic acidemia of which mechanism relies on increase in cAMP NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) 2023-10-03 — — US claimed
CN-116200330-A Method for down-regulating MAPK8 expression to induce reprogramming of cells into mammary epithelial cells 广西壮族自治区人民医院 2023-06-02 — — CN claimed
US-20010009907-A1 Compositions and methods for preventing restenosis following revascularization procedures DISCOVERY THERAPEUTICS, INC. 2001-07-26 — — US claimed
EP-1014995-A1 COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES Discovery Therapeutics, Inc. (US) 2000-07-05 — — EP claimed
US-5942497-A Purine compound and catecholamine compound containing compositions and methods for administration ADENOCOMP, LLC 1999-08-24 — — US claimed
EP-0735888-A4 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA ATSUO F (US) 1999-05-12 — — EP claimed
WO-1998057651-A1 COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES DISCOVERY THERAPEUTICS, INC. (US) 1998-12-23 — — WO claimed
US-5679650-A SIDE EFFECT REDUCTION ADENOCOMP, LLC 1997-10-21 — — US claimed
US-5573772-A PROTECTING AN ORGAN HAVING A3 ADENOSINE RECEPTORS BY ADMINISTERING A3 ADENOSINE RECEPTOR AGONIST BY ORAL, INTRAVENOUS OR PERFUSION TECHNIQUE GENSIA, INC. (US) 1996-11-12 — — US claimed
EP-0735888-A1 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA, Atsuo F. (US) 1996-10-09 — — EP claimed
US-5424297-A Adenosine dextran conjugates UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1995-06-13 — — US claimed
WO-1995014478-A1 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA ATSUO F (US) 1995-06-01 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250090673-A1 CONJUGATE FOR TARGETING CENTRAL NERVOUS SYSTEM PYGB, PMP22, GMFG AHCY 4557/4885HIF1A 1584/4885TMEM97 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.